Compare iShares MSCI ACWI ETF (ACWI) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI ACWI ETF vs Neurocrine Biosciences Inc — how do they compare? iShares MSCI ACWI ETF trades at $161.26, while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: iShares MSCI ACWI ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ACWI | NBIX | |
|---|---|---|
52-Week High | $161.44 | $185.50 |
52-Week Low | $132.04 | $123.10 |
Market Cap | — | $16.76B |
Sector | — | Health |
Enterprise Value | — | $16.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACWI (iShares MSCI ACWI ETF) trades at $161.44, up 0.84% with a bullish technical signal from moving averages, though oscillators show caution. The ETF benefits from strong global earnings growth and a forward P/E of 15.5x as of Seeking Alpha on July 7, 2026. Recent institutional activity includes Bank of New York Mellon adjusting its stake, reflecting ongoing investor interest in global equity exposure, particularly in technology sectors.
The outlook for ACWI is supported by robust EPS growth and technical momentum, but risks include market volatility and sector concentration. Investors may find opportunity in its diversified global holdings, though overbought conditions near resistance at $162 warrant monitoring for pullbacks to support at $160.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI ACWI ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
